MedTrace Logo

A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis

NCT06844799 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2025-02-25

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.

Conditions

  • Moderate-to-severe Plaque Psoriasis

Interventions

DRUG

HS-20137

HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.

DRUG

Placebo&HS-20137

Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-10
Primary Completion
2027-03-31
Completion
2027-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06844799 on ClinicalTrials.gov